ロード中...

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

Introduction Cetuximab is registered for use in colorectal cancer (CRC) patients with RAS wild-type tumours only. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS. We hypothesize that the activitated KRAS pathway in KRAS...

詳細記述

保存先:
書誌詳細
出版年:Invest New Drugs
主要な著者: Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., Guchelaar, H. J.
フォーマット: Artigo
言語:Inglês
出版事項: Springer US 2015
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648966/
https://ncbi.nlm.nih.gov/pubmed/26386973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0285-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!